Completion of Placement and SPP raises $48.9M in total
Filed with ASX · · 2 pages · English
Starpharma Holdings Limited on 6ix
Story so far
Earlier from Starpharma
- Starpharma receives $5.7M R&D tax incentive refund
- Share Purchase Plan offer document
- Starpharma completes oversubscribed A$45M placement
- SPL7013 COVID-19 nasal spray virucidal against SARS-CoV-2
- Starpharma awarded $1M MRFF funding for COVID-19 spray
Later from Starpharma
- SPL7013 shows potent antiviral activity in RSV
- VIRALEZE COVID-19 nasal spray to be ready for market Q1CY21
- VIRALEZE COVID-19 nasal spray study to commence in January
- Change in substantial holding
- AZD0466 clinical DEP program global expansion
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma